Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Prediction of response to pemetrexed in non-small-cell lung cancer with immunohistochemical phenotyping based on gene expression profiles.

Visser S, Hou J, Bezemer K, de Vogel LL, Hegmans JPJJ, Stricker BH, Philipsen S, Aerts JGJV.

BMC Cancer. 2019 May 14;19(1):440. doi: 10.1186/s12885-019-5645-x.

2.

Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy.

Noordam L, Kaijen MEH, Bezemer K, Cornelissen R, Maat LAPWM, Hoogsteden HC, Aerts JGJV, Hendriks RW, Hegmans JPJJ, Vroman H.

Oncoimmunology. 2018 Jul 30;7(12):e1474318. doi: 10.1080/2162402X.2018.1474318. eCollection 2018.

3.

Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human.

Aerts JGJV, de Goeje PL, Cornelissen R, Kaijen-Lambers MEH, Bezemer K, van der Leest CH, Mahaweni NM, Kunert A, Eskens FALM, Waasdorp C, Braakman E, van der Holt B, Vulto AG, Hendriks RW, Hegmans JPJJ, Hoogsteden HC.

Clin Cancer Res. 2018 Feb 15;24(4):766-776. doi: 10.1158/1078-0432.CCR-17-2522. Epub 2017 Dec 12.

4.

Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.

Dammeijer F, Lievense LA, Kaijen-Lambers ME, van Nimwegen M, Bezemer K, Hegmans JP, van Hall T, Hendriks RW, Aerts JG.

Cancer Immunol Res. 2017 Jul;5(7):535-546. doi: 10.1158/2326-6066.CIR-16-0309. Epub 2017 May 23.

5.

Stereotactic Ablative Radiotherapy Induces Peripheral T-Cell Activation in Patients with Early-Stage Lung Cancer.

de Goeje PL, Smit EF, Waasdorp C, Schram MTB, Kaijen-Lambers MEH, Bezemer K, de Mol M, Hartemink KJ, Nuyttens JJME, Maat APWM, Hegmans JPJJ, Hendriks RW, Senan S, Aerts JGJV.

Am J Respir Crit Care Med. 2017 Nov 1;196(9):1224-1227. doi: 10.1164/rccm.201610-2178LE. No abstract available.

PMID:
28345951
6.

Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Dammeijer F, Lievense LA, Veerman GD, Hoogsteden HC, Hegmans JP, Arends LR, Aerts JG.

J Clin Oncol. 2016 Sep 10;34(26):3204-12. doi: 10.1200/JCO.2015.66.3955. Epub 2016 Jul 18. Review.

PMID:
27432922
7.

Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression.

Lievense LA, Cornelissen R, Bezemer K, Kaijen-Lambers ME, Hegmans JP, Aerts JG.

J Thorac Oncol. 2016 Oct;11(10):1755-64. doi: 10.1016/j.jtho.2016.06.021. Epub 2016 Jul 12.

8.

Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients.

Lievense LA, Bezemer K, Cornelissen R, Kaijen-Lambers ME, Hegmans JP, Aerts JG.

Lung Cancer. 2017 May;107:36-40. doi: 10.1016/j.lungcan.2016.04.015. Epub 2016 Apr 27.

PMID:
27168021
9.

Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma.

Cornelissen R, Hegmans JP, Maat AP, Kaijen-Lambers ME, Bezemer K, Hendriks RW, Hoogsteden HC, Aerts JG.

Am J Respir Crit Care Med. 2016 May 1;193(9):1023-31. doi: 10.1164/rccm.201508-1573OC.

PMID:
26652184
10.

Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer.

de Goeje PL, Bezemer K, Heuvers ME, Dingemans AC, Groen HJ, Smit EF, Hoogsteden HC, Hendriks RW, Aerts JG, Hegmans JP.

Oncoimmunology. 2015 Mar 19;4(7):e1014242. eCollection 2015 Jul.

11.

Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma.

Cornelissen R, Lievense LA, Robertus JL, Hendriks RW, Hoogsteden HC, Hegmans JP, Aerts JG.

Lung Cancer. 2015 Jun;88(3):332-7. doi: 10.1016/j.lungcan.2015.03.013. Epub 2015 Mar 21.

PMID:
25843042
12.

Immunotherapy prospects in the treatment of lung cancer and mesothelioma.

Aerts JG, Lievense LA, Hoogsteden HC, Hegmans JP.

Transl Lung Cancer Res. 2014 Feb;3(1):34-45. doi: 10.3978/j.issn.2218-6751.2013.11.04. Review.

13.

Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma.

Cornelissen R, Lievense LA, Maat AP, Hendriks RW, Hoogsteden HC, Bogers AJ, Hegmans JP, Aerts JG.

PLoS One. 2014 Sep 5;9(9):e106742. doi: 10.1371/journal.pone.0106742. eCollection 2014.

14.

Immunomodulation in cancer.

Hegmans JP, Aerts JG.

Curr Opin Pharmacol. 2014 Aug;17:17-21. doi: 10.1016/j.coph.2014.06.007. Epub 2014 Jul 8. Review.

PMID:
25011112
15.

Biomarkers for immune checkpoint inhibitors.

Lievense LA, Hegmans JP, Aerts JG.

Lancet Oncol. 2014 Jan;15(1):e1. doi: 10.1016/S1470-2045(13)70557-6. No abstract available.

PMID:
24384488
16.

Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma.

Mahaweni NM, Kaijen-Lambers ME, Dekkers J, Aerts JG, Hegmans JP.

J Extracell Vesicles. 2013 Oct 24;2. doi: 10.3402/jev.v2i0.22492. eCollection 2013.

17.

Immunological profiling as a means to invigorate personalized cancer therapy.

Hegmans JP, Aerts JG.

Oncoimmunology. 2013 Aug 1;2(8):e25236. Epub 2013 Jun 10.

18.

Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients.

Heuvers ME, Muskens F, Bezemer K, Lambers M, Dingemans AC, Groen HJM, Smit EF, Hoogsteden HC, Hegmans JPJJ, Aerts JGJV.

Lung Cancer. 2013 Sep;81(3):468-474. doi: 10.1016/j.lungcan.2013.06.005. Epub 2013 Jul 11.

PMID:
23850196
19.

Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer.

Aerts JG, Hegmans JP.

Cancer Res. 2013 Apr 15;73(8):2381-8. doi: 10.1158/0008-5472.CAN-12-3932. Epub 2013 Apr 11. Review.

20.

Tumor-associated macrophages in thoracic malignancies.

Lievense LA, Bezemer K, Aerts JG, Hegmans JP.

Lung Cancer. 2013 Jun;80(3):256-62. doi: 10.1016/j.lungcan.2013.02.017. Epub 2013 Mar 13. Review.

PMID:
23489559
21.

Improving lung cancer survival; time to move on.

Heuvers ME, Hegmans JP, Stricker BH, Aerts JG.

BMC Pulm Med. 2012 Dec 13;12:77. doi: 10.1186/1471-2466-12-77.

22.

Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment.

Heuvers ME, Aerts JG, Cornelissen R, Groen H, Hoogsteden HC, Hegmans JP.

BMC Cancer. 2012 Dec 5;12:580. doi: 10.1186/1471-2407-12-580. Review.

23.

Dendritic cell-based immunotherapy in mesothelioma.

Cornelissen R, Lievense LA, Heuvers ME, Maat AP, Hendriks RW, Hoogsteden HC, Hegmans JP, Aerts JG.

Immunotherapy. 2012 Oct;4(10):1011-22. doi: 10.2217/imt.12.108. Review.

PMID:
23148753
24.

New roads open up for implementing immunotherapy in mesothelioma.

Cornelissen R, Heuvers ME, Maat AP, Hendriks RW, Hoogsteden HC, Aerts JG, Hegmans JP.

Clin Dev Immunol. 2012;2012:927240. doi: 10.1155/2012/927240. Epub 2012 Jun 24. Review.

25.

History of tuberculosis as an independent prognostic factor for lung cancer survival.

Heuvers ME, Aerts JG, Hegmans JP, Veltman JD, Uitterlinden AG, Ruiter R, Rodenburg EM, Hofman A, Bakker M, Hoogsteden HC, Stricker BH, van Klaveren RJ.

Lung Cancer. 2012 Jun;76(3):452-6. doi: 10.1016/j.lungcan.2011.12.008. Epub 2012 Jan 9.

PMID:
22226628
26.

[Exosomes and cancer].

de Vrij J, Maas SL, Hegmans JP, Lamfers ML, Dirven CM, Broekman ML.

Ned Tijdschr Geneeskd. 2011;155(51):A3677. Review. Dutch.

PMID:
22200143
27.

Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B.

Tjwa ET, van Oord GW, Hegmans JP, Janssen HL, Woltman AM.

J Hepatol. 2011 Feb;54(2):209-18. doi: 10.1016/j.jhep.2010.07.009. Epub 2010 Sep 6.

PMID:
21095036
28.

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.

Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG, Hegmans JP.

BMC Cancer. 2010 Aug 30;10:464. doi: 10.1186/1471-2407-10-464.

29.

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma.

Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Hegmans JP, Aerts JG.

Br J Cancer. 2010 Aug 24;103(5):629-41. doi: 10.1038/sj.bjc.6605814. Epub 2010 Jul 27.

30.

Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity.

Veltman JD, Lambers ME, van Nimwegen M, de Jong S, Hendriks RW, Hoogsteden HC, Aerts JG, Hegmans JP.

J Biomed Biotechnol. 2010;2010:798467. doi: 10.1155/2010/798467. Epub 2010 May 23.

31.

Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.

Hegmans JP, Veltman JD, Lambers ME, de Vries IJ, Figdor CG, Hendriks RW, Hoogsteden HC, Lambrecht BN, Aerts JG.

Am J Respir Crit Care Med. 2010 Jun 15;181(12):1383-90. doi: 10.1164/rccm.200909-1465OC. Epub 2010 Feb 18.

PMID:
20167848
32.

Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS.

Hegmans JP, Veltman JD, Fung ET, Verch T, Glover C, Zhang F, Allard WJ, T'Jampens D, Hoogsteden HC, Lambrecht BN, Aerts J.

Technol Cancer Res Treat. 2009 Oct;8(5):323-32.

PMID:
19754208
33.

Exosomes.

Hegmans JP, Gerber PJ, Lambrecht BN.

Methods Mol Biol. 2008;484:97-109. doi: 10.1007/978-1-59745-398-1_7.

PMID:
18592175
34.

Gene expression profiling and gene copy-number changes in malignant mesothelioma cell lines.

Zanazzi C, Hersmus R, Veltman IM, Gillis AJ, van Drunen E, Beverloo HB, Hegmans JP, Verweij M, Lambrecht BN, Oosterhuis JW, Looijenga LH.

Genes Chromosomes Cancer. 2007 Oct;46(10):895-908.

PMID:
17620293
35.

HIF1a expression in bronchial biopsies correlates with tumor microvascular saturation determined using optical spectroscopy.

Aerts JG, Amelink A, van der Leest C, Hegmans JP, Hemmes A, den Hamer B, Sterenborg HC, Hoogsteden HC, Lambrecht BN.

Lung Cancer. 2007 Sep;57(3):317-21. Epub 2007 May 7.

PMID:
17485134
36.

Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses.

Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN.

Eur Respir J. 2006 Jun;27(6):1086-95. Epub 2006 Mar 15.

37.

Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells.

Hegmans JP, Hemmes A, Aerts JG, Hoogsteden HC, Lambrecht BN.

Am J Respir Crit Care Med. 2005 May 15;171(10):1168-77. Epub 2005 Mar 11.

PMID:
15764728
38.

Proteomic analysis of exosomes secreted by human mesothelioma cells.

Hegmans JP, Bard MP, Hemmes A, Luider TM, Kleijmeer MJ, Prins JB, Zitvogel L, Burgers SA, Hoogsteden HC, Lambrecht BN.

Am J Pathol. 2004 May;164(5):1807-15.

39.

Proteomic analysis of exosomes isolated from human malignant pleural effusions.

Bard MP, Hegmans JP, Hemmes A, Luider TM, Willemsen R, Severijnen LA, van Meerbeeck JP, Burgers SA, Hoogsteden HC, Lambrecht BN.

Am J Respir Cell Mol Biol. 2004 Jul;31(1):114-21. Epub 2004 Feb 19.

PMID:
14975938
40.

Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness.

Verhoeven GT, Hegmans JP, Mulder PG, Bogaard JM, Hoogsteden HC, Prins JB.

Thorax. 2002 Aug;57(8):694-700.

41.

A model system for optimising the selection of membrane antigen-specific human antibodies on intact cells using phage antibody display technology.

Hegmans JP, Radosevic K, Voerman JS, Burgers JA, Hoogsteden HC, Prins JB.

J Immunol Methods. 2002 Apr 1;262(1-2):191-204.

PMID:
11983233
42.

The IL-1 system in psoriatic skin: IL-1 antagonist sphere of influence in lesional psoriatic epidermis.

Debets R, Hegmans JP, Croughs P, Troost RJ, Prins JB, Benner R, Prens EP.

J Immunol. 1997 Mar 15;158(6):2955-63.

PMID:
9058835
43.

Expression of cytokines and their receptors by psoriatic fibroblasts. II. decreased TNF receptor expression.

Debets R, Hegmans JP, Buurman WA, Benner R, Prens EP.

Cytokine. 1996 Jan;8(1):80-8.

PMID:
8742070
44.

Expression of cytokines and their receptors by psoriatic fibroblast. I. Altered IL-6 synthesis.

Debets R, Hegmans JP, Deleuran M, Hooft S, Benner R, Prens EP.

Cytokine. 1996 Jan;8(1):70-9.

PMID:
8742069
45.

Effects of cyclosporine on cytokines and cytokine receptors in psoriasis.

Prens EP, van Joost T, Hegmans JP, t Hooft-Benne K, Ysselmuiden OE, Benner R.

J Am Acad Dermatol. 1995 Dec;33(6):947-53.

PMID:
7490364

Supplemental Content

Loading ...
Support Center